AI-generated research brief — verify at source
Romiplostim Cuts Chemotherapy Dose Modifications More Than Twofold Versus Placebo
In a phase 3 randomized controlled trial, romiplostim allowed 84% of patients with chemotherapy-induced thrombocytopenia to continue chemotherapy without dose modifications, compared with just 36% on placebo — more than twice the rate (risk ratio 2.77, 95% CI 1.78–4.30). This represents a clinically meaningful advance in a condition for which no widely approved treatment has previously existed.
What Was Studied
The trial investigated whether romiplostim, a thrombopoietin receptor agonist that stimulates platelet production, could reduce the impact of chemotherapy-induced thrombocytopenia (CIT) on the ability to maintain planned chemotherapy dosing. CIT is a frequent complication that forces dose reductions or delays, potentially compromising cancer treatment efficacy, and until now has lacked an approved pharmacological remedy.
How It Was Studied
The RECITE trial was a phase 3, international, double-blind, randomized, placebo-controlled study enrolling 165 patients with persistent CIT, defined as a platelet count of 85×10⁹/L or below. Patients were assigned approximately 2:1 to either romiplostim (n=109) or placebo (n=56). The study population was heavily weighted toward gastrointestinal cancers: 75% had colorectal cancer, 13% had gastroesophageal cancer, and 12% had pancreatic cancer. A substantial proportion had advanced disease, with 72% of romiplostim patients and 61% of placebo patients carrying a stage 4 diagnosis. The trial was funded by Amgen and the Biomedical Advanced Research and Development Authority.
What Was Observed
- Chemotherapy dose maintenance was dramatically better with romiplostim: 84% of treated patients (92 of 109) avoided any CIT-induced modification to their chemotherapy regimen, compared with only 36% (20 of 56) on placebo. This translates to roughly 2.8 times the likelihood of maintaining full dosing (risk ratio 2.77, 95% CI 1.78–4.30, P<0.001), with the odds ratio indicating more than tenfold greater odds in the romiplostim group (OR 10.16, 95% CI 4.44–23.72, P<0.001).
- Grade 3 or higher adverse events were more common in the romiplostim group (37%) than in the placebo group (22%), but investigators attributed this differential primarily to the effects of chemotherapy itself rather than the study drug, reflecting the higher rate of continued treatment in the romiplostim arm.
- Drug-related adverse events were infrequent and generally mild: investigator-attributed treatment-related events occurred in 12% of romiplostim patients versus 7% on placebo. The most frequently reported were nausea (2% in each group) and headache (2% with romiplostim). Critically, none were classified as serious, and none resulted in death or discontinuation of romiplostim, placebo, or chemotherapy.
- Thromboembolic events, a theoretical concern with platelet-stimulating agents, occurred in 2% of romiplostim patients and in none of the placebo patients, a finding that warrants monitoring in future research given the small absolute numbers.
Why This Matters
Chemotherapy-induced thrombocytopenia has long been an undertreated clinical problem with no approved standard-of-care pharmacotherapy, forcing oncologists to compromise dose intensity and potentially treatment outcomes. This trial provides the first phase 3 evidence that a thrombopoietin receptor agonist can substantially reduce CIT-driven dose modifications, with a safety profile that appears manageable. The findings position romiplostim as a candidate for regulatory review in this indication and may reshape supportive care protocols in oncology.
How to Read This Result
While the effect size is large and statistically robust, the trial enrolled a specific population dominated by gastrointestinal cancers with a 2:1 allocation ratio and a relatively modest overall sample size, which may limit direct generalisability to other tumor types or chemotherapy regimens.
Limitations
The abstract does not explicitly report study limitations.